TY  - JOUR
A1  - Thaçi, Diamant
A1  - Puig, Lluís
A1  - Reich, Kristian
A1  - Tsai, Tsen-Fang
A1  - Tyring, Stephen
A1  - Kingo, Kulli
A1  - Ziv, Michael
A1  - Pinter, Andreas
A1  - Vender, Ronald
A1  - Lacombe, Aude
A1  - Xia, Summer
A1  - Bhosekar, Vaishali
A1  - Gilloteau, Isabelle
A1  - Guana, Adriana
A1  - Blauvelt, Andrew
T1  - Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : results from the CLEAR study
T2  - Journal of the American Academy of Dermatology
N2  - Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin 17A, a key cytokine involved in the development of psoriasis. Secukinumab has shown long-lasting efficacy and safety in the complete spectrum of psoriatic disease, including disease localized to nails, scalp, palms and soles, and joints (peripheral and axial arthritis). Given the chronic and relapsing nature of psoriasis, long-term data might help to fully characterize the efficacy and safety profile of secukinumab as well as its impact on quality of life.
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50752
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-507521
SN  - 1097-6787
SN  - 0190-9622
N1  - 2019 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
VL  - 81
IS  - 6
SP  - 1405
EP  - 1409
PB  - Elsevier
CY  - Amsterdam [u. a.]
ER  -